Dasatinib pill bioequivalence study in healthy adults
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial compares how a 100 mg dasatinib pill moves through the body (blood levels) to check that two forms work the same way. It is done in healthy adults, so it may help improve how dasatinib is reliably made and prescribed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be a man age 18 to 50
- Be judged by the study doctor as clinically healthy, with normal lab test results
- Not smoke for the last 3 months
- Have a body mass index (BMI) between 18 and 30
- Be able to follow the visit schedule and have complete contact information
- Agree by signing informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the drug dasatinib (a pill) for people with acute myeloid leukemia (AML) whose disease did not respond to a standard combination of venetoclax and azacitidine. The goal is to see if dasatinib alone can help control the leukemia when other treatments have failed.
This study tests whether two medicines (dasatinib and quercetin) can affect “cell aging” in people with chronic kidney disease related to diabetes. You may be asked to take pills for a short period and complete follow-up visits to measure how your body responds.
This trial tests a combination of two drugs, dasatinib and ropeginterferon, for people newly diagnosed with chronic myeloid leukemia (CML) in its early chronic phase. The goal is to see if the combination works safely and helps control the disease.
This study tests a new biosimilar drug called QL2109, which is similar to daratumumab (a treatment for multiple myeloma). Healthy men aged 18-50 will receive one dose to see how the body processes it and if it causes any side effects.
This trial tests whether the drug dasatinib can reduce the hidden HIV reservoir in people who have had their virus well-controlled on HIV medications for a long time. It may help move toward a cure by targeting the cells where HIV hides.
This trial tests whether adding two drugs, dasatinib and quercetin, to CAR-T therapy can help people with multiple myeloma that has come back or not responded to past treatments. It aims to make the CAR-T cells work better and reduce side effects.
Hear when a new Myeloma Multiple trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.